In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

Perspective Therapeutics Inc (CATX) stock saw a modest uptick, ending the day at $4.01 which represents a slight increase of $0.38 or 10.47% from the prior close of $3.63. The stock opened at $3.64 ...

Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherenceLOS ALTOS, ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American ...

Perspective Therapeutics Inc (CATX) stock saw a modest uptick, ending the day at $3.43 which represents a slight increase of $0.27 or 8.54% from the prior close of $3.16. The stock opened at $3.18 and ...

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers ...

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers through ...